Skip to content

PHARMACYTE BIOTECH, INC.: 10-Q filed 2023-12-15

What PHARMACYTE BIOTECH, INC. reported in its quarterly report filed 2023-12-15 (fiscal Q2 2024): 36 published measures, 109 facts as tagged in accession 0001683168-23-008889.

This filing

Form
10-Q (quarterly report)
Filed
2023-12-15
Fiscal period
fiscal Q2 2024
Accession
0001683168-23-008889 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PHARMACYTE BIOTECH, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-10-3178,877,766USD
At 2023-04-3073,276,925USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-10-3120,812,589USD
At 2023-04-30586,581USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-10-3136,767,508USD
At 2023-07-3139,193,789USD
At 2023-04-3072,690,344USD
At 2022-10-3181,037,572USD
At 2022-07-3186,295,714USD
At 2022-04-3089,919,766USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-10-3173,425,269USD
At 2023-04-3068,039,936USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-08-01 to 2023-10-312,789,896USD92
2023-05-01 to 2023-10-31-393,401USD184
2023-05-01 to 2023-07-31-3,183,297USD92
2022-08-01 to 2022-10-31-1,880,507USD92
2022-05-01 to 2022-10-31-3,425,519USD184
2022-05-01 to 2022-07-31-1,545,012USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-05-01 to 2023-10-31-1,641,395USD184
2022-05-01 to 2022-10-31-2,963,642USD184

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2023-08-01 to 2023-10-310USD92
2023-05-01 to 2023-10-310USD184
2022-08-01 to 2022-10-310USD92
2022-05-01 to 2022-10-310USD184

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-05-01 to 2023-10-317,027,868USD184
2022-05-01 to 2022-10-31-5,475,011USD184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-05-01 to 2023-10-310USD184
2022-05-01 to 2022-10-310USD184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-10-31-116,352,174USD
At 2023-04-30-115,958,773USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-08-01 to 2023-10-318,765,134shares92
2023-05-01 to 2023-10-3110,683,514shares184
2022-08-01 to 2022-10-3120,585,451shares92
2022-05-01 to 2022-10-3120,742,383shares184

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-08-01 to 2023-10-318,765,134shares92
2023-05-01 to 2023-10-3110,683,514shares184
2022-08-01 to 2022-10-3120,585,451shares92
2022-05-01 to 2022-10-3120,742,383shares184

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-08-01 to 2023-10-31-0.26USD/shares92
2023-05-01 to 2023-10-31-0.85USD/shares184
2022-08-01 to 2022-10-31-0.09USD/shares92
2022-05-01 to 2022-10-31-0.17USD/shares184

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-08-01 to 2023-10-31-0.26USD/shares92
2023-05-01 to 2023-10-31-0.85USD/shares184
2022-08-01 to 2022-10-31-0.09USD/shares92
2022-05-01 to 2022-10-31-0.17USD/shares184

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-05-01 to 2023-10-310USD184
2022-05-01 to 2022-10-316,667USD184

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-08-01 to 2023-10-31-1,409,520USD92
2023-05-01 to 2023-10-31-3,484,846USD184
2022-08-01 to 2022-10-31-2,318,620USD92
2022-05-01 to 2022-10-31-3,999,228USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-10-3173,748,458USD
At 2023-04-3068,147,617USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-10-315,239,589USD
At 2023-04-30586,581USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-10-31126,163USD
At 2023-04-30128,281USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2023-08-01 to 2023-10-31164,953USD92
2023-05-01 to 2023-10-3126,622,277USD184
2022-05-01 to 2022-10-315,475,891USD184

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-08-01 to 2023-10-311,409,520USD92
2023-05-01 to 2023-10-313,484,846USD184
2022-08-01 to 2022-10-312,318,620USD92
2022-05-01 to 2022-10-313,999,228USD184

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-08-01 to 2023-10-3182,033USD92
2023-05-01 to 2023-10-31186,516USD184
2022-08-01 to 2022-10-31177,996USD92
2022-05-01 to 2022-10-31337,269USD184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-10-318,699,992shares
At 2023-04-3016,793,980shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-10-3173,425,269USD
At 2023-04-3068,039,936USD
At 2022-10-3176,962,587USD
At 2022-04-3085,400,656USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-10-31193,590,781USD
At 2023-04-30202,230,583USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2023-10-31-24,143USD
At 2023-04-30-23,003USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2023-10-313,549,427USD
At 2023-04-303,549,427USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2023-10-311,018,155USD
At 2023-04-30458,300USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2023-10-31323,189USD
At 2023-04-30107,681USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2023-08-01 to 2023-10-312,788,305USD92
2023-05-01 to 2023-10-31-394,541USD184
2022-08-01 to 2022-10-31-1,881,227USD92
2022-05-01 to 2022-10-31-3,424,935USD184

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2023-08-01 to 2023-10-31-2,258,087USD92
2023-05-01 to 2023-10-31-9,033,266USD184
2022-08-01 to 2022-10-31-1,880,507USD92
2022-05-01 to 2022-10-31-3,425,519USD184

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-08-01 to 2023-10-31272,517USD92
2023-05-01 to 2023-10-311,627,919USD184
2022-08-01 to 2022-10-31183,043USD92
2022-05-01 to 2022-10-31427,712USD184

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2023-08-01 to 2023-10-31-765USD92
2023-05-01 to 2023-10-31-2,614USD184
2022-08-01 to 2022-10-31-1,058USD92
2022-05-01 to 2022-10-31-4,964USD184

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-08-01 to 2023-10-314,199,416USD92
2023-05-01 to 2023-10-313,091,445USD184
2022-08-01 to 2022-10-31438,113USD92
2022-05-01 to 2022-10-31573,709USD184

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2023-05-01 to 2023-10-311,600USD184
2022-05-01 to 2022-10-310USD184

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2023-05-01 to 2023-10-31-2,118USD184
2022-05-01 to 2022-10-31655,916USD184

Inspect the source

Entity
PHARMACYTE BIOTECH, INC. / CIK 0001157075
Captured
2026-09-20T07:42:36.237Z
SEC response SHA-256
8f9ad1662a11f3cb167c6975b558c6cce5e582ddebd7699a946a7cffe2a40413

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001157075.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))